MCKESSON CORP (MCK)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for MCK
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| MCK | Retired President and CEO | 64 | ["Retired President and CEO, H. Lundbeck A/S"] | ["Audit Committee","Finance Committee"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| RARE | Board member and advisor to various life science companies | 63 | ["President and Chief Executive Officer of H. Lundbeck A/S", "President and Chief Executive Officer and director of Xtuit Pharmaceuticals, Inc.", "President and Chief Executive Officer and director of FORUM Pharmaceuticals Inc.", "Corporate officer at Takeda Pharmaceutical Company Limited", "Director at Takeda Pharmaceutical Company Limited", "President and Chief Executive Officer and director of Millennium Pharmaceuticals, Inc.", "President and Chief Executive Officer of Millennium: The Takeda Oncology Company", "Various roles at Novartis Pharma AG"] | ["Research and Development Committee"] | 2026 |
Biography sourced from the proxy statement filing.
Retired President and Chief Executive Officer, H. Lundbeck A/S
Age: 64
Director since: 2024
Committees: Audit Finance
Director Qualification Highlights: Healthcare Industry Business Transformation
PROFESSIONAL EXPERIENCE AND BACKGROUND
Dr. Dunsire served as president and chief executive officer of H. Lundbeck A/S, a biopharmaceutical company specializing in developing and delivering transformative therapies for brain diseases, from 2018 to 2023. From 2017 to 2018, she served as president and chief executive officer of XTuit Pharmaceuticals, a biopharmaceutical company focused on cancer treatments. Prior to her employment with XTuit Pharmaceuticals, Dr. Dunsire held various executive leadership roles at FORUM Pharmaceuticals, Millennium: The Takeda Oncology Company and Millennium Pharmaceuticals. Dr. Dunsire started her career as a primary care physician in Johannesburg, South Africa and received her medical degree from the University of Witwatersrand in Johannesburg, South Africa.
SKILLS AND QUALIFICATIONS
Dr. Dunsire brings to the Board deep healthcare and clinical experience, including leadership of large, complex biopharmaceutical companies, as well as experience in healthcare operations and clinical research. She also brings a unique perspective with her clinical background and expertise in the pharmaceutical and oncology areas, which align with McKesson s strategic growth priorities.
OTHER PUBLIC COMPANY BOARDS
Current: Ultragenyx Pharmaceutical Inc.
Past Five Years: Alexion Pharmaceuticals Inc. (2018 2021), Syros Pharmaceuticals, Inc. (2021 2024)